MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
2.870
+0.060
+2.14%
Opening 10:11 01/30 EST
OPEN
2.810
PREV CLOSE
2.810
HIGH
2.940
LOW
2.810
VOLUME
29.45K
TURNOVER
33.92K
52 WEEK HIGH
6.30
52 WEEK LOW
0.8500
MARKET CAP
23.42M
P/E (TTM)
-0.8964
1D
5D
1M
3M
1Y
5Y
Oppenheimer Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)
TipRanks · 8h ago
Soleno Therapeutics Announces Peer-Reviewed Publication Of Results From Previously Completed Phase 3 Trial Of DCCR For Treatment Of Prader-Willi Syndrome
Benzinga · 4d ago
Kala Pharmaceuticals, Getty Images And This Bitcoin Stock Top Short Squeeze Leaderboard: 10 Short Squeeze Stocks To Watch
Benzinga · 01/17 16:38
Watching Soleno Therapeutics; Zacks Investment Research Upgrades To Strong Buy
Benzinga · 01/13 17:58
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 12/27/2022 18:27
Peering Into Soleno Therapeutics's Recent Short Interest
Benzinga · 12/20/2022 16:11
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/20/2022 13:07
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket
Benzinga · 12/20/2022 11:13
More
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for the treatment of rare diseases. Its lead drug, Diazoxide Choline Controlled-Release tablets (DCCR), is a potent ATP-sensitive potassium (KATP) channel activator. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like Prader-Willi syndrome (PWS) to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance, and reduce body fat. It appears that many of the problematic behaviors in conditions like PWS may have hyperphagic drive as a root cause and may therefore be improved by addressing hyperphagia. The Company has a Fast-Track designation for DCCR in PWS and an orphan drug designation for the drug in the United States and European Union. Its development pipeline includes proposed diagnostic devices for asthma in children.

Webull offers kinds of Soleno Therapeutics Inc stock information, including NASDAQ:SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.